Monica Mendez, MD
Hematology-Oncology · Bayamon, PRNPI 1477580983
Payments from drug & device makers
Across 483 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$1K
- Merck$1K
- E.r. Squibb & Sons, L.L.C.$960
- PBG Puerto Rico LLC$886
- Eli Lilly Export S.A. Puerto Rico Branch$791
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,60795%
- Education$5025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 59 | $1,570 |
| AstraZeneca(2 entities) | 61 | $1,396 |
| Merck | 49 | $1,021 |
| E.r. Squibb & Sons, L.L.C. | 38 | $960 |
| PBG Puerto Rico LLC | 44 | $886 |
| Eli Lilly Export S.A. Puerto Rico Branch | 36 | $791 |
| Genentech USA, Inc. | 31 | $635 |
| AbbVie | 22 | $525 |
| Novartis | 23 | $501 |
| Amgen | 24 | $486 |
| Sanofi | 18 | $401 |
| Sobi, Inc | 10 | $239 |
| Bayer Puerto Rico Inc. | 10 | $239 |
| Puma Biotechnology, Inc. | 8 | $215 |
| Rigel Pharmaceuticals, Inc. | 9 | $189 |
| Exelixis Inc. | 5 | $125 |
| Abbott | 1 | $98 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Pfizer | 2 | $93 |
| Bayer | 4 | $90 |
| Incyte Corporation | 4 | $86 |
| Astellas Pharma US Inc | 4 | $78 |
| Beigene USA, Inc. | 3 | $61 |
| GSK | 2 | $52 |
| Tempus AI, Inc | 2 | $51 |
| Eisai Inc. | 1 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $36 |
| Bristol Myers Squibb | 1 | $27 |
| EMD Serono, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Caris MPI, Inc. | 1 | $20 |
| Seagen Inc. | 1 | $20 |
| Verastem, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 160 | $2,551,099 |
| PromactaEltrombopag Olamine | 86 | $1,086,737 |
| VerzenioAbemaciclib | 52 | $811,550 |
| RevlimidLenalidomide | 34 | $625,177 |
| LenvimaLenvatinib Mesylate | 14 | $353,664 |
| NerlynxNeratinib Maleate | 14 | $310,091 |
| JakafiRuxolitinib Phosphate | 21 | $298,649 |
| SprycelDasatinib | 20 | $211,584 |
| LynparzaOlaparib | 13 | $195,698 |
| ImbruvicaIbrutinib | 11 | $183,728 |
| InqoviDecitabine/Cedazuridine | 15 | $124,927 |
| RetacritEpoetin Alfa-Epbx | 47 | $124,231 |
| ProliaDenosumab | 43 | $75,893 |
| XgevaDenosumab | 19 | $61,520 |
| XareltoRivaroxaban | 36 | $30,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Retacrit, Eliquis | $93 | $2,695,745239 claims |
| NovartisPromacta | $501 | $1,086,73786 claims |
| Bristol Myers SquibbRevlimid | $27 | $625,17734 claims |
| Eisai Inc.Lenvima | $43 | $353,66414 claims |
| Puma Biotechnology, Inc.Nerlynx | $215 | $310,09114 claims |
| Incyte CorporationJakafi | $86 | $298,64921 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $960 | $211,58420 claims |
| AstraZenecaLynparza | $1,396 | $195,69813 claims |
| AmgenProlia, Xgeva | $486 | $137,41362 claims |
| Johnson & JohnsonXarelto | $1,570 | $30,43136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Bayamon
- Pedro Gil Solivan OrtizRio Piedras$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.